News headlines about Foundation Medicine (NASDAQ:FMI) have been trending positive this week, Alpha One Sentiment reports. The research group, a unit of Accern, identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Foundation Medicine earned a news sentiment score of 0.27 on Alpha One’s scale. Alpha One also gave media stories about the company an impact score of 71 out of 100, indicating that recent media coverage is likely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have effected AlphaOne’s analysis:

FMI has been the subject of a number of recent research reports. William Blair restated a “buy” rating on shares of Foundation Medicine in a research report on Monday, April 3rd. Zacks Investment Research upgraded Foundation Medicine from a “sell” rating to a “hold” rating in a research report on Thursday, April 6th. Finally, Janney Montgomery Scott upgraded Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 target price for the company in a research report on Tuesday, March 7th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $27.33.

Shares of Foundation Medicine (NASDAQ:FMI) traded up 0.15% during mid-day trading on Friday, reaching $32.35. The company’s stock had a trading volume of 117,580 shares. Foundation Medicine has a 52-week low of $15.10 and a 52-week high of $35.30. The company has a 50-day moving average price of $31.97 and a 200 day moving average price of $24.02. The company’s market cap is $1.15 billion.

Foundation Medicine (NASDAQ:FMI) last issued its earnings results on Wednesday, February 22nd. The company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.06. The firm had revenue of $28.80 million for the quarter, compared to the consensus estimate of $29.23 million. Foundation Medicine had a negative net margin of 84.67% and a negative return on equity of 42.21%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned ($0.55) earnings per share. Equities analysts expect that Foundation Medicine will post ($3.95) earnings per share for the current year.

In other news, SVP Robert W. Hesslein sold 6,231 shares of Foundation Medicine stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $31.67, for a total value of $197,335.77. Following the transaction, the senior vice president now directly owns 104,305 shares in the company, valued at approximately $3,303,339.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Steven J. Kafka sold 10,415 shares of Foundation Medicine stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $23.24, for a total value of $242,044.60. Following the completion of the transaction, the chief operating officer now owns 146,015 shares in the company, valued at $3,393,388.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 81,214 shares of company stock valued at $2,605,785. 2.20% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.

5 Day Chart for NASDAQ:FMI

Receive News & Stock Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related stocks with our FREE daily email newsletter.